当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Saeed Ahmed, Mariyah Hussain, Hooria Manzoor, Venkatesh Sreeram, Sara Dar, Sharmeen Amin, Rizwan Ahmed, Mustafa Qureshi, Satneet Singh, Archana Rao Adikey, Swati Sood, Muhammad Taha Farooq and Tazeen Azfar
Major depressive disorder (MDD) is one of the most prevalent psychiatric disorders in the HIV-positive population. For long periods of time, MDD has been treated with conventional antidepressant therapy in these patients. Novel Antidepressant Therapy for Major Depression in HIV-infected adults is associated with various side effects such as sleep disturbance, nervousness, insomnia, weight loss, and sexual dysfunction that could lead to non-adherence to antiretroviral therapy. To uphold compliance and prevent patients from serious adverse effects of antidepressant therapy; emerging noninvasive innovative transcranial direct current stimulation (tDCS) could serve as a better alternative. tDCS has shown promising results; it is an effective, safe therapeutic strategy with an immediate onset of action as compared to conventional SSRI therapy. The application of tDCS is an easy one and the device for conducting this treatment modality is highly portable. Along with its convenient application, subjects who have been treated with tDCS in study settings, found it tolerable with minimum discomfort and without developing chronic and profound adverse effects. The role of transcranial direct current stimulation therapy is not limited to addressing solely the depressive component in the MDD population; however, it could be critical in assisting these patients by combating their co-morbidities of alcoholism and substance abuse by decreasing their cravings. Furthermore, tDCS has proven itself in improving the cognition in this patient population. This paper will further review this innovative treatment option and will also suggest tDCS to be studied in larger clinical trials as it could serve a huge role in developing better understanding of patient experiences regarding its tolerability, safety, and efficacy. Similarly, it will also provide important evidence to clinicians for the development of better practices in this area.